Reckitt Mucinex Patent Gets Reprieve As Appeals Court Rules Against Perrigo
This article was originally published in The Tan Sheet
Executive Summary
An appeals court decision against Perrigo further delays the private labeler's plans to launch a Mucinex equivalent, leaving the Reckitt Benckiser decongestant still unchallenged by generic competition
You may also be interested in...
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011
Perrigo Targets October For Quality System Corrections, FDA Re-Inspection
Perrigo wants FDA to re-inspect its Allegan, Mich., manufacturing plant in October, when the private labeler intends to have corrected its quality system failings that elicited a warning letter in April